Abstract
Background and Aim: Staining for hepatitis B viral antigens is often done in liver biopsies from patients with chronic hepatitis B, but its correlates with clinical phenotypes are not well described. Methods: Biopsies were collected from a large cohort of adults and children with chronic hepatitis B viral infection through the Hepatitis B Research Network. Immunohistochemical staining of sections was done for hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) and then centrally read by the pathology committee. The degree of liver injury and pattern of staining were then correlated with clinical characteristics, including the clinical phenotype of hepatitis B. Results: Biopsies from 467 subjects were studied, including 46 from children. Immunostaining for HBsAg was positive in 417 (90%) with scattered hepatocyte staining being the most common pattern. HBsAg staining correlated best with serum levels of HBsAg and hepatitis B viral DNA; the absence of HBsAg staining was often a prelude to loss of HBsAg from serum. HBcAg staining was positive in 225 (49%), and, while cytoplasmic staining was more frequent than nuclear staining, both nuclear and cytoplasmic positivity were often seen in the same specimen. Staining for HBcAg correlated with both level of viremia and liver injury. No biopsies from inactive carriers had stainable HBcAg, while 91% of the biopsies from those with hepatitis B e antigen-positive chronic hepatitis B stained positively for HBcAg. Conclusion: Immunostaining for hepatitis B viral antigens may yield helpful insights into liver disease pathogenesis but appears to add little to commonly used serological and biochemical blood tests.
Original language | English |
---|---|
Pages (from-to) | 989-998 |
Number of pages | 10 |
Journal | Journal of Gastroenterology and Hepatology (Australia) |
Volume | 38 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2023 |
Keywords
- hepatitis B, clinical
- hepatology
- hepatology, hepatitis B, immunology
- hepatology, hepatitis B, virology
Fingerprint
Dive into the research topics of 'Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Gastroenterology and Hepatology (Australia), Vol. 38, No. 6, 06.2023, p. 989-998.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Immunostaining for hepatitis B viral antigens in liver
T2 - Association with clinical, biochemical, and virologic features of disease
AU - for the Hepatitis B Research Network
AU - Kleiner, David E.
AU - Lisker-Melman, Mauricio
AU - Wahed, Abdus S.
AU - Bhan, Atul K.
AU - Nalesnik, Michael A.
AU - Choi, Eun Young K.
AU - Leonard, Kelsey K.
AU - Ghany, Marc G.
AU - Chung, Raymond T.
AU - Di Bisceglie, Adrian M.
AU - Lau, Daryl T.Y.
AU - Roberts, Lewis R.
AU - Hassan, Mohamed A.
AU - Schwarzenberg, Sarah Jane
AU - Teckman, Jeffrey
AU - Janssen, Harry L.A.
AU - Wong, David K.
AU - Juan, Joshua
AU - Feld, Jordan
AU - Yim, Colina
AU - Patel, Keyur
AU - Ling, Simon C.
AU - Lee, William M.
AU - Murakami, Carol S.
AU - Perrillo, Robert
AU - Do, Son
AU - Rodriguez-Baez, Norberto
AU - Han, Steven Huy B.
AU - Tran, Tram T.
AU - Terrault, Norah A.
AU - Khalili, Mandana
AU - Cooper, Stewart L.
AU - Rosenthal, Philip
AU - Lok, Anna Suk Fong
AU - Fontana, Robert J.
AU - Tsai, Naoky
AU - Younoszai, Barak
AU - Fried, Michael W.
AU - Muir, Andrew
AU - Evon, Donna
AU - Darling, Jama M.
AU - Carithers, Robert C.
AU - Shuhart, Margaret
AU - Kowdley, Kris V.
AU - Wang, Chia C.
AU - Murray, Karen F.
AU - Sterling, Richard K.
AU - Luketic, Velimir A.
AU - Schwarz, Kathleen B.
AU - Liang, T. Jake
AU - Hoofnagle, Jay H.
AU - Doo, Edward
AU - Chang, Kyong Mi
AU - Park, Jang June
AU - Belle, Steven H.
AU - King, Wendy C.
N1 - Funding Information: In addition to the authors, the HBRN would like to acknowledge the contributions of the following: Harvard Consortium: Jianghe Niu, PhD, Asad Javaid, MBBS, Bilal Nasir, MBBS, Ammu Susheela, MBBS, Imad Nasser, MD (Beth Israel Deaconess Medical Center, Boston, MA), Arley Donovan, Nifasha Rusibamayila, Cara Foley (Massachusetts General Hospital, Boston, MA). Minnesota Alliance for Research in Chronic Hepatitis B: Alisha C. Stahler, Linda Stadheim, RN (Mayo Clinic Rochester, Rochester, MN), John Lake, MD, Philip Lacher (University of Minnesota, Minneapolis, MN), Shannon M. Riggs, LPN, AS (Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, MN). Midwest Hepatitis B Consortium: Kathryn Rushing, RN, Rosemary A. Nagy, RDN, LD, MBA, Jacki Cerkoski, RN, MSN (Saint Louis University School of Medicine, St. Louis, MO), Debra DeMarco Shaw, RN, BSN, Lisa Kessels, RN, Michael K. Klebert, PhD, RN, ANP-BC (Washington University School of Medicine, St. Louis, MO). University of Toronto Consortium: Seham Noureldin, PhD, Danie La, RN, Lucie Liu, MSc, CCRP, Diana Kaznowski, RN, Jiayun Chen, Fengfei Huang, Doinita Vladutu, Orlando Cerocchi (Toronto General Hospital, Toronto, Ontario), Athena Hau, BSc (Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario). HBV CRN North Texas Consortium: Debra Rowan, LVN (Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center at Dallas, Dallas, TX), Sheila Bass (University of Texas Southwestern, Dallas, TX), Barbara Lilly, BS (Baylor University Medical Center, Dallas, TX), Laurie A. Rodgers-Augustyniak, RN, Shirley Montanye, RN (Department of Pediatrics, UTSW, Dallas, TX). Los Angeles Hepatitis B Consortium: Samuel French, MD, Velma Peacock, RN (David Geffen School of Med, UCLA, Los Angeles, CA). San Francisco Hepatitis B Research Group Consortium: Marion Peters, MD, Ashley Shobe, MS, Rayshawnda Davis, Romuald Kuras, Claudia Ayala, MS, Ivy Lau, BS (University of California-San Francisco, San Francisco, CA), Veronika Podolskaya, BS, NCPT, Anna von Bakonyi, LVN, CCRC, Nata DeVole, RN (California Pacific Medical Center Research Institute, San Francisco, CA), Natasha Feier, MS, Joel Feier, BS, Camille Langlois, MS (Department of Pediatrics, UCSF, San Francisco, CA). Michigan Hawaii Consortium: Barbara McKenna, MD, Karen Choi, MD, Kelly Oberhelman, PAC, Sravanthi Kaza, Bpharm, Isabel Moran (University of Michigan, Ann Arbor, MI), Leslie Huddleston, NP, Richmond Wong (The Queen's Medical Center, University of Hawaii, Honolulu, HI). Chapel Hill, NC Consortium: A. Sidney Barritt, MD, Tiffany Marsh, BA, Vikki Metheny, ANP, Danielle Cardona, PA-C (University of North Carolina at Chapel Hill, Chapel Hill, NC). Virginia Commonwealth University Medical Center: Paula G. Smith, RN, BSN, Charlotte Hofmann, RN (Virginia Commonwealth University Health System, Richmond, VA). PNW/Alaska Clinical Center Consortium: Alycia Wolfstone, RN, MN (University of Washington Medical Center, Seattle, WA), Jody Mooney, Lupita Cardona-Gonzalez (Virginia Mason Medical Center, Seattle, WA), Kara L. Cooper (Center for Clinical and Translational Research, Seattle Children's Institute, Seattle, WA). Johns Hopkins University: Hongxia Li, MBBS, MS, Douglas Mogul, MD, Robert Anders, MD, PhD, Hejab Imteyaz, Peter Lee, MD, Kiyoko Oshima, MD, Kim Kafka, RN, Naureen Islam, BS (Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, MD). Liver Diseases Branch, NIDDK, NIH: Nancy Fryzek, RN, BSN, Elenita Rivera, BSN, Nevitt Morris, Vanessa Haynes-Williams, Amy Huang, RN, Catherine Nadal, RN, MS, Jaha Norman-Wheeler, RN, BA (National Institutes of Health, Bethesda, MD). Liver Disease Research Branch, NIDDK, NIH: Averell H. Sherker, MD, Rebecca J. Torrance, RN, MS, Sherry R. Hall, MS (National Institutes of Health, Bethesda, MD). Immunology Center: Mary E. Valiga, RN, Keith Torrey, BS, Danielle Levine, BS, James Keith, BS, Michael Betts, PhD (University of Pennsylvania, Philadelphia, PA), Luis J. Montaner, DVM, DPhil (Wistar Institute, Philadelphia, PA). Data Coordinating Center: Frani Averbach, MPH, Tamara Haller, Regina Hardison, MS, Stephanie Kelley, MS, Christina M. Lalama, MS, Sharon Lawlor, MBA, Hsing-Hua S. Lin, MS, PhD, Manuel Lombardero, MS, Andrew Pelesko, BS, Donna Stoliker, Melissa Weiner, MPH, Ella Zadorozny, MS, Qian Zhao, PhD (Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA). Funding Information: The HBRN was funded as a Cooperative Agreement between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the following investigators: Lewis R. Roberts, MB, ChB, PhD (U01‐DK082843), Anna Suk‐Fong Lok, MD (U01‐DK082863), Steven H. Belle, PhD, MScHyg (U01‐DK082864), Kyong‐Mi Chang, MD (U01‐DK082866), Michael W. Fried, MD (U01‐DK082867), Adrian M. Di Bisceglie, MD (U01‐DK082871), William M. Lee, MD (U01‐DK082872), Harry L. A. Janssen, MD, PhD (U01‐DK082874), Daryl T.‐Y. Lau, MD, MPH (U01‐DK082919), Richard K. Sterling, MD, MSc (U01‐DK082923), Steven‐Huy B. Han, MD (U01‐DK082927), Robert C. Carithers, MD (U01‐DK082943), Mandana Khalili, MD (U01‐DK082944), Kathleen B. Schwarz, MD (U01‐DK082916), an interagency agreement with NIDDK: Lilia M. Ganova‐Raeva, PhD (A‐DK‐3002‐001), and support from the intramural program, NIDDK, NIH: Marc G. Ghany, MD. Additional funding to support this study was provided to Kyong‐Mi Chang, MD, the Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306 and NIH Public Health Service Research Grant M01‐RR00040), Richard K. Sterling, MD, MSc (UL1TR000058, NCATS [National Center for Advancing Translational Sciences, NIH]), Norah A. Terrault, MD, MPH (Clinical and Translational Science Awards [CTSA] Grant Number UL1TR000004), Michael W. Fried, MD (CTSA Grant Number UL1TR001111), Anna Suk‐Fong Lok (CTSA Grant Numbers UL1RR024986, U54TR001959), and Kathleen B. Schwarz, MD (CTSA Grant Number UL1TR000423). Additional support was provided by Gilead Sciences, Inc. and Roche Molecular Systems through Cooperative Research and Development Agreements (CRADAs) with the NIDDK and by Roche/Genentech through a Clinical Trials Agreement (CTA) with the NIDDK. Financial support: Publisher Copyright: © 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
PY - 2023/6
Y1 - 2023/6
N2 - Background and Aim: Staining for hepatitis B viral antigens is often done in liver biopsies from patients with chronic hepatitis B, but its correlates with clinical phenotypes are not well described. Methods: Biopsies were collected from a large cohort of adults and children with chronic hepatitis B viral infection through the Hepatitis B Research Network. Immunohistochemical staining of sections was done for hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) and then centrally read by the pathology committee. The degree of liver injury and pattern of staining were then correlated with clinical characteristics, including the clinical phenotype of hepatitis B. Results: Biopsies from 467 subjects were studied, including 46 from children. Immunostaining for HBsAg was positive in 417 (90%) with scattered hepatocyte staining being the most common pattern. HBsAg staining correlated best with serum levels of HBsAg and hepatitis B viral DNA; the absence of HBsAg staining was often a prelude to loss of HBsAg from serum. HBcAg staining was positive in 225 (49%), and, while cytoplasmic staining was more frequent than nuclear staining, both nuclear and cytoplasmic positivity were often seen in the same specimen. Staining for HBcAg correlated with both level of viremia and liver injury. No biopsies from inactive carriers had stainable HBcAg, while 91% of the biopsies from those with hepatitis B e antigen-positive chronic hepatitis B stained positively for HBcAg. Conclusion: Immunostaining for hepatitis B viral antigens may yield helpful insights into liver disease pathogenesis but appears to add little to commonly used serological and biochemical blood tests.
AB - Background and Aim: Staining for hepatitis B viral antigens is often done in liver biopsies from patients with chronic hepatitis B, but its correlates with clinical phenotypes are not well described. Methods: Biopsies were collected from a large cohort of adults and children with chronic hepatitis B viral infection through the Hepatitis B Research Network. Immunohistochemical staining of sections was done for hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) and then centrally read by the pathology committee. The degree of liver injury and pattern of staining were then correlated with clinical characteristics, including the clinical phenotype of hepatitis B. Results: Biopsies from 467 subjects were studied, including 46 from children. Immunostaining for HBsAg was positive in 417 (90%) with scattered hepatocyte staining being the most common pattern. HBsAg staining correlated best with serum levels of HBsAg and hepatitis B viral DNA; the absence of HBsAg staining was often a prelude to loss of HBsAg from serum. HBcAg staining was positive in 225 (49%), and, while cytoplasmic staining was more frequent than nuclear staining, both nuclear and cytoplasmic positivity were often seen in the same specimen. Staining for HBcAg correlated with both level of viremia and liver injury. No biopsies from inactive carriers had stainable HBcAg, while 91% of the biopsies from those with hepatitis B e antigen-positive chronic hepatitis B stained positively for HBcAg. Conclusion: Immunostaining for hepatitis B viral antigens may yield helpful insights into liver disease pathogenesis but appears to add little to commonly used serological and biochemical blood tests.
KW - hepatitis B, clinical
KW - hepatology
KW - hepatology, hepatitis B, immunology
KW - hepatology, hepatitis B, virology
UR - http://www.scopus.com/inward/record.url?scp=85152434636&partnerID=8YFLogxK
U2 - 10.1111/jgh.16167
DO - 10.1111/jgh.16167
M3 - Article
C2 - 36890337
AN - SCOPUS:85152434636
SN - 0815-9319
VL - 38
SP - 989
EP - 998
JO - Journal of Gastroenterology and Hepatology (Australia)
JF - Journal of Gastroenterology and Hepatology (Australia)
IS - 6
ER -